Zobrazeno 1 - 10
of 160
pro vyhledávání: '"M. E. Gore"'
Autor:
Richard Marais, Grazia Saturno, Robert McLeary, Cyril Fisher, Udai Banerji, Alfonso Zambon, Lawrence Davies, Rebecca Lee, J.M.G. Larkin, Natasha Preece, Emma Dean, Paul Lorigan, Dan Niculescu-Duvaz, Matthew G Krebs, Amaya Viros, Nathalie Dhomen, Malin Pedersen, L. Johnson, Filipa Lopes, Caroline J. Springer, D. Holovanchuk, M. E. Gore, Ion Niculescu-Duvaz
Publikováno v:
Annals of Oncology
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Saturno, G, Lopes, F, Niculescu-Duvaz, I, Niculescu-Duvaz, D, Zambon, A, Davies, L, Johnson, L, Preece, N, Lee, R, Viros Usandizaga, A, Holovanchuk, D, Pedersen, M, Mcleary, R, Lorigan, P, Dhomen, N, Fisher, C, Banerji, U, Dean, E, Krebs, M, Gore, M, Larkin, J, Marais, R & Springer, C 2021, ' The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers ', Annals of Oncology, vol. 32, no. 2, pp. 269-278 . https://doi.org/10.1016/j.annonc.2020.10.483
Background KRAS is mutated in ∼90% of pancreatic ductal adenocarcinomas, ∼35% of colorectal cancers and ∼20% of non-small-cell lung cancers. There has been recent progress in targeting G12CKRAS specifically, but therapeutic options for other mu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9dd4c81e95c2a5d81da34368a411222
http://europepmc.org/articles/PMC7839839
http://europepmc.org/articles/PMC7839839
Autor:
Gerard Walls, James Larkin, E. Kalaitzaki, Lavinia Spain, Maximilian Julve, K. O’Meara, Jeremy Rees, M. E. Gore, Samra Turajlic, Thomas A. Schmid
Publikováno v:
Annals of Oncology. 28:377-385
Background: Treatment with immune checkpoint inhibitors (ICPi) has greatly improved survival for patients with advanced melanoma in recent years. Anti-CTLA-4 and anti-PD1 antibodies have been approved following large Phase III trials. Immunerelated n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02582b5e0f37f5bf60c46170a8dca4a2
https://doi.org/10.1093/annonc/mdw558
https://doi.org/10.1093/annonc/mdw558
Autor:
Angela George, A Kapoor, Alexandra Taylor, A Kumar, Susana Banerjee, M. E. Gore, Susan Lalondrelle
Publikováno v:
ePoster.
Introduction/Background Treatment for ovarian cancer (OC) usually involves systemic therapy (ST) and surgery. Radiotherapy (RT) is used for palliation, however for limited relapse may provide improved local control (LC) and defer the need for ST. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21f9edbc6e1f81b33d937d38a8b885f7
https://doi.org/10.1136/ijgc-2019-esgo.781
https://doi.org/10.1136/ijgc-2019-esgo.781
Autor:
Jennifer Thomas, Robert D. Goldin, Rooshi Nathwani, T Cross, Charalambos G. Antoniades, James Larkin, Lavinia Spain, Lewis Au, M. Backhouse, R. Bowen, A. Gurung, M. E. Gore, R. Morrison, Samra Turajlic, C. Barlow, T. Tillett, C. Herbert
Publikováno v:
Liver.
Background Immune checkpoint inhibitors (CPI) against lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) are a novel therapeutic breakthrough in an increasing number of malignancies. CPI induced acute liver injury (ALI) is the second mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e922ab4695f2c7d5c9df0bfae9b80a21
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.227
https://doi.org/10.1136/gutjnl-2018-bsgabstracts.227
Autor:
Jennifer Brown, M.J.A. de Jonge, Yvette Drew, M. E. Gore, Sook-Hee Hong, M. Ferguson, C. Gresty, M. Learoyd, K. Meyer, M. Lanasa, M Tang, Young-Ae Park, Susan M. Domchek, P. Herbolsheimer, Anita Wolfer, Helen K. Angell, Ricardo H. Alvarez
Publikováno v:
Gynecologic Oncology. 149:246-247
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::438bd8c5b66ab9dfc25bda924f59a1a7
https://doi.org/10.1016/j.ygyno.2018.04.555
https://doi.org/10.1016/j.ygyno.2018.04.555
Autor:
L. Del Rosario, Sergio A. Quezada, Lisa Pickering, Fiona Byrne, Charles Swanton, Kevin Litchfield, Roberto Salgado, José I. López, Emine Hatipoglu, Steven Hazell, Samra Turajlic, Benjamin M. Chain, Stuart Horswell, James Larkin, Andrew Rowan, M. E. Gore, Lewis Au, David Nicol, Nicos Fotiadis
Publikováno v:
Annals of Oncology. 30:v359
Background ADATPeR is the first prospective study evaluating the role of anti-PD1 agents in the neoadjuvant setting prior to cytoreductive nephrectomy in treatment-naive patients with metastatic clear cell renal cell carcinoma (mccRCC). We performed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::da6794435be58b92964fd382d78e47d6
https://doi.org/10.1093/annonc/mdz249.006
https://doi.org/10.1093/annonc/mdz249.006
Autor:
M. Kneissl, Paul Lorigan, Mark R. Middleton, B Bahamon, Adil Daud, Ruth Plummer, S Skaria, E Hoberman, Pippa Corrie, Anna C. Pavlick, S. Zhang, Drew W. Rasco, L. Rangachari, Anthony J. Olszanski, Sanjiv S. Agarwala, Ricardo J. Gonzalez, M. E. Gore, C. Herbert
Publikováno v:
Annals of Oncology. 28:v136-v137
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::436bc77e0f6f4872e9db2f2466517956
https://doi.org/10.1093/annonc/mdx367.043
https://doi.org/10.1093/annonc/mdx367.043
Autor:
Martin G. Cook, R.M. Mackie, Christy Walker, J. Marsden, Neil H. Cox, Pippa Corrie, Barry Powell, Howard Peach, Paul Nathan, Julia Newton-Bishop, Paul Lorigan, M. E. Gore, L. Burrows
Publikováno v:
British Association of Dermatologists' Management Guidelines. :118-204
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8875b97a12a82e0424253c54193272e8
https://doi.org/10.1002/9781444329865.ch3
https://doi.org/10.1002/9781444329865.ch3
Publikováno v:
Annals of Oncology. 29:ix84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b20db47fd71677f2e265037a2b978009
https://doi.org/10.1093/annonc/mdy436.020
https://doi.org/10.1093/annonc/mdy436.020
Autor:
C. Herbert, M. E. Gore, J.M.G. Larkin, Lewis Au, R. Morrison, Lavinia Spain, Rooshi Nathwani, Charalambos G. Antoniades, A. Gurung, R. Bowen, Jennifer Thomas, T. Tillett, Robert D. Goldin, Samra Turajlic, C. Barlow, Lucia A. Possamai, T Cross, M. Backhouse
Publikováno v:
Annals of Oncology. 29:viii430
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::098bcbb41cc45c6ae750b47d06e3540d
https://doi.org/10.1093/annonc/mdy288.084
https://doi.org/10.1093/annonc/mdy288.084